Nyrada is an Australian publicly-listed (ASX: NYR) preclinical stage, drug development company. The Company specialises in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases.
The Company’s vision is to become a high growth pharmaceutical company specialising in drug discovery and early stage drug development. The Company focuses on areas of substantial unmet clinical need and has identified drug candidates with significant therapeutic and commercial potential, where few if any, effective or well-tolerated therapies exist.
The Company has four current drug development programs:
- Cardiovascular: a PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs
- Neuroprotection: a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury
- Inflammation/pain: a drug to treat pain associated with peripheral nerve damage, and
- Inflammation/autoimmunity: a drug to treat autoimmune diseases such as psoriasis.
The Company’s two lead programs are the cardiovascular program and the neuroprotection program.
The cardiovascular program involves the development of a cholesterol-lowering drug. The aim here is an oral, small molecule drug that effectively lowers cholesterol. The mechanism of action is via the inhibition of the plasma protein, PCSK9, an action known to assist standard-of-care statin drugs in achieving target cholesterol. Our objective is to combine our PCSK9 inhibitor with a generic statin into a single tablet, offering a novel, convenient dual-purpose medication that can be taken once daily.
Our ultimate aim is to help approximately half of individuals with blood cholesterol levels considered to be putting them at risk of cardiovascular disease (heart attack or stroke) who do not respond adequately to statin drug therapy or who cannot tolerate effective dosages of statins.
The neuroprotection program involves the development of a drug to block secondary brain damage that occurs following a stroke or traumatic brain injury (TBI), such as severe head trauma from contact sports, a fall, or a motor vehicle accident.
In the US, a stroke occurs every 40 seconds and a TBI every 15 seconds. The combined economic burden for stroke and TBI, in the US amounts to more than US$100 billion in direct and indirect costs.
The aim here is to reduce the long-term disability associated with stroke or traumatic brain injury by limiting the number of brain cells that die post injury.
Treatment with a neuroprotectant drug is intended to improve patient outcomes and increase the likelihood of recovery, shorten rehabilitation times, and reduce the economic burden to the health system.